EN
/
JP
News
About Us
About Us
Philosophy/Policy
Directors/Executive Management
History
Company Information
Corporate Governance
Partner
Close
Business Strategy
Business Strategy
Business Model
Life Cycle Management Strategy
Close
Technology
Technology
SLC Transporters
LAT1 Inhibitors
Close
Pipeline
Pipeline
Development Status
Biliary Tract Cancer
Multiple Sclerosis
Other Pipelines
Close
Clinical Trials
Clinical Trials
Biliary Tract Cancer Phase III
Biliary Tract Cancer Investigator-Initiated Clinical Trial
JPH034 Phase I
Close
IR
IR
IR News
Top Message
Disclosure Policy
Financial Highlights
IR Calendar
IR Library
Financial Results
Presentation Materials
IR Materials
Stock Information
Stock Overview
General Meeting of Shareholders
Disclaimer
Close
Contact
EN
/
JP
Close
Top
＞
News Lists
News Lists
All
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2024.12.25
Announcement of presentation at the J.P. Morgan Healthcare Conference 2025
2024.12.23
J-Pharma Selected as the “ NEXT UNICORN 2024” by the Nihon Keizai Shimbun (Nikkei)
2024.10.01
IND Application to Initiate Clinical Trials of NANVURANLAT for Cancer Patients Approved by U.S. FDA
2024.09.30
Results of a Phase II Trial of NANVURANLAT in Japan Published in Clinical Cancer Research
2024.07.10
Nikkei Biotech featured our pipeline to capture the global market in the article “Clinical Development Pipeline of Drug Discovery Start-Ups 2024”
2024.07.03
J-Pharma announces its selection for AMED’s FY2024 “Drug Discovery Venture Ecosystem Enhancement Project
2024.06.28
Notice of Board of Directors Appointments
2024.06.03
Conclusion of License Agreement with Georgetown University
2024.05.16
Corporate Website Renewal Announcement
2024.01.22
J-Pharma Presented the latest findings on LAT1 inhibitor NANVURANLAT (development code: JPH203) at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium (ASCO GI2024)
1
2
3
4
5
6
7
8
